BioSpace News Archive

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported fourth quarter and full year 2019 financial results.

The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Thursday 16 April 2020, at 16.00 pm in Orexo’s facilities at Rapsgatan 7E in Uppsala, Sweden.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced fourth quarter and full year 2019 financial results, as well as business updates,

Seelos Therapeutics, Inc. ( announced today the closing of its previously announced underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. The net proceeds to Seelos from this offering are expected to be approximately $3.9 million, after de

Mustang Bio, Inc. today announced financial results and recent corporate highlights for the full year ended December 31, 2019. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are

Broad network of labs will use automated cobas SARS-CoV-2 Test to process high volume of patient samples sent from across US

Celltex Therapeutics Corporation (“Celltex”), a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. Celltex has researched safety and efficacy from the use o

Provides ADVANZ PHARMA with an immediate and direct commercial presence in Germany , France , Spain , Italy , and the Benelux region, while strengthening its existing presence in the Nordics and the United Kingdom Further diversifies ADVANZ PHARMA’s portfolio of medicines by adding established and innovative high-quality brands that are sold in more than 60 countries around

CASI Pharmaceuticals today reported financial results for the year ended December 31, 2019.

Mark Tryniski to Stand for Reelection as Director but Will Not Stand for Reappointment as Chair